Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8517516 | 0.82 | KMT2A (0.43) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL9647013 | 0.77 | KMT2A (0.49) | KMT2ATDP1MAPTALDH1A1RAB9A | |
| SCHEMBL312287 | 0.77 | KMT2A (0.92) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL10590135 | 0.76 | CA1 (0.44) | KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL22388846 | 0.76 | KMT2A (0.76) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL19720791 | 0.75 | KMT2A (0.69) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL18467576 | 0.75 | KMT2A (0.69) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL27589165 | 0.74 | TDP1 (0.92) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL8761637 | 0.74 | CA2 (0.68) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL11511490 | 0.74 | KMT2A (0.67) | KMT2ATDP1SLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040005708-A1 | Polypeptide derivatives and nucleic acid carriers containing the same | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-01-08 | — | — | US | claimed |
| EP-1285942-A1 | POLYPEPTIDE DERIVATIVES AND NUCLEIC ACID CARRIERS CONTAINING THE SAME | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-02-26 | — | — | EP | claimed |
| US-20040005708-A1 | Polypeptide derivatives and nucleic acid carriers containing the same | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1285942-A1 | POLYPEPTIDE DERIVATIVES AND NUCLEIC ACID CARRIERS CONTAINING THE SAME | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040005708-A1 | Polypeptide derivatives and nucleic acid carriers containing the same | POLRMT, TAP1, RNASE1 | KMT2A 4379/4885TDP1 30/4885SLC6A2 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.